UnitedHealth Group Inc. (NYSE:UNH) is one of the most oversold S&P 500 stocks in 2025, declining substantially due to weak quarterly results, guidance revision, CEO departure, and guidance suspension. Analysts like Barclays’ Andrew Mok and Wolfe Research’s Justin Lake have lowered price targets but maintain Buy ratings on the stock.

As UnitedHealth approaches Q2 2025 earnings, analyst Andrew Mok lowered the price target to $337, citing reduced earnings per share forecast for 2026. Despite the adjustment, he remains positive about the company’s long-term potential but takes a more cautious stance on short-term earnings outlook.

Wolfe Research analyst Justin Lake also reduced UnitedHealth’s price target to $330 from $363, maintaining a Buy rating. Lake attributes the lower target to headwinds in Medicaid and health insurance exchanges, as well as increased expenses to align the company.

UnitedHealth Group Inc. (NYSE:UNH) offers health insurance and healthcare solutions in the U.S. and globally under UnitedHealthcare and Optum brands. Despite its potential, some analysts believe other AI stocks may offer greater upside potential and lower downside risk.

For more investment opportunities, check out Harvard University Stock Portfolio: Top 10 Stock Picks and 20 Undervalued Momentum Stocks that are Taking Off. This article is originally published on Insider Monkey.

Read more at Yahoo Finance: Analysts Trim Price Targets but See Long-Term Value in UnitedHealth (UNH)